Acadian Asset Management
STRO icon

Acadian Asset Management’s Sutro Biopharma STRO Stock Holding History

Acadian Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.36M Sell
335,813
-2,140
-0.6% -$38.7K 0.01% 573
2025
Q4 		$3.91M Sell
337,953
-979
-0.3% -$9.29K 0.01% 720
2025
Q3 		$2.94M Buy
338,932
+34,708
+11% +$295K 0.01% 793
2025
Q2 		$2.17M Sell
304,224
-9,235
-3% -$75.5K ﹤0.01% 804
2025
Q1 		$2.04M Buy
313,459
+138,266
+79% +$2.18M 0.01% 751
2024
Q4 		$3.22M Buy
175,193
+14,206
+9% +$434K 0.01% 645
2024
Q3 		$5.57M Buy
160,987
+3,491
+2% +$137K 0.02% 481
2024
Q2 		$4.61M Buy
157,496
+37,071
+31% +$1.47M 0.01% 525
2024
Q1 		$6.8M Buy
120,425
+28,122
+30% +$1.24M 0.02% 393
2023
Q4 		$3.96M Buy
92,303
+14,916
+19% +$473K 0.02% 517
2023
Q3 		$2.68M Buy
77,387
+11,940
+18% +$520K 0.01% 604
2023
Q2 		$3.04M Sell
65,447
-3,277
-5% -$163K 0.01% 584
2023
Q1 		$3.17M Buy
68,724
+12,541
+22% +$796K 0.01% 581
2022
Q4 		$4.54M Sell
56,183
-6,997
-11% -$486K 0.02% 470
2022
Q3 		$3.5M Sell
63,180
-2,982
-5% -$176K 0.02% 499
2022
Q2 		$3.45M Buy
66,162
+42,346
+178% +$2.37M 0.02% 501
2022
Q1 		$1.96M Buy
23,816
+9,444
+66% +$899K 0.01% 669
2021
Q4 		$2.14M Sell
14,372
-3,857
-21% -$691K 0.01% 642
2021
Q3 		$3.44M Sell
18,229
-4,018
-18% -$764K 0.01% 540
2021
Q2 		$4.13M Sell
22,247
-1,492
-6% -$292K 0.02% 517
2021
Q1 		$5.4M Buy
23,739
+11,723
+98% +$2.78M 0.02% 457
2020
Q4 		$2.61M Sell
12,016
-675
-5% -$112K 0.01% 686
2020
Q3 		$1.27M Buy
12,691
+3,334
+36% +$315K 0.01% 813
2020
Q2 		$726K Buy
9,357
+462
+5% +$44.3K ﹤0.01% 1065
2020
Q1 		$908K Buy
8,895
+4,350
+96% +$457K 0.01% 823
2019
Q4 		$501K Buy
4,545
+1,474
+48% +$152K ﹤0.01% 1072
2019
Q3 		$279K Buy
3,071
+2,165
+239% +$219K ﹤0.01% 1236
2019
Q2 		$103K Buy
906
+844
+1,361% +$93K ﹤0.01% 1365
2019
Q1 		$7K Buy
+62
New +$6.45K ﹤0.01% 1889

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management's STRO Position: Q1 2026 in Review

Acadian Asset Management reduced its Sutro Biopharma (STRO) stake by 0.63% in Q1 2026, selling an estimated $38.7K and leaving 335,813 shares worth $8.36M. The position accounts for 0.01% of the portfolio, ranked #573.

Acadian Asset Management first reported a position in STRO in Q1 2019 and has held it in 29 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Acadian Asset Management held 335,813 shares of Sutro Biopharma worth $8.36M as of Q1 2026.
  • Acadian Asset Management sold 2,140 Sutro Biopharma shares in Q1 2026, an estimated $38.7K.
  • Sutro Biopharma made up 0.01% of Acadian Asset Management's portfolio in Q1 2026, its #573 holding.
  • Acadian Asset Management first reported a position in Sutro Biopharma in Q1 2019 and has held it in 29 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.